GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Other Current Assets

Galderma Group AG (XSWX:GALD) Other Current Assets : CHF65 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Other Current Assets?

Galderma Group AG's other current assets for the quarter that ended in Dec. 2024 was CHF65 Mil.

Galderma Group AG's quarterly other current assets declined from Dec. 2023 (CHF56 Mil) to Jun. 2024 (CHF21 Mil) but then increased from Jun. 2024 (CHF21 Mil) to Dec. 2024 (CHF65Mil).

Galderma Group AG's annual other current assets increased from . 20 (CHF0 Mil) to Dec. 2023 (CHF56 Mil) increased from Dec. 2023 (CHF56 Mil) to Dec. 2024 (CHF65 Mil).


Galderma Group AG Other Current Assets Historical Data

The historical data trend for Galderma Group AG's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Other Current Assets Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Other Current Assets
56.21 65.09

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Other Current Assets - 56.21 21.45 65.09

Galderma Group AG Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Galderma Group AG Other Current Assets Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines